Charles River Laboratories Intl. Inc vs Iris Energy Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $286.79 (market cap $13.46B), while Iris Energy Limited trades at $43.92 (market cap $14.20B). The key difference: Charles River Laboratories Intl. Inc and Iris Energy Limited are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals.
| CRL | IREN | |
|---|---|---|
Market Cap | $13.46B | $14.20B |
Sector | Health | Energy |
52-Week High | $282.00 | $76.41 |
52-Week Low | $145.57 | $17.73 |
Enterprise Value | $16.30B | $15.95B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
IREN stock trades at $43.17, up 11.44% today amid positive AI infrastructure news. The technical picture is neutral with resistance near $42. Fundamentally, the company shows strong revenue growth to $501M in 2025 and has secured $2.8B in new AI contracts, though it has missed recent EPS estimates and reports negative ROE and ROA. Analyst sentiment is bullish with a $84.43 price target.
Outlook is driven by AI cloud expansion but carries execution risks. The stock offers growth potential from its $4B revenue target, yet high valuations and recent earnings misses pose challenges. Investors should weigh contract momentum against profitability concerns and sector volatility.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →